Several studies have focused on the CD209-positive DCs in cancer tissue, such as cutaneous squamous cell carcinoma [40,41], oral squamous cell carcinoma [42], renal cell carcinoma [43,44], prostate intraductal carcinoma [45], breast cancer [46], hepatocellular carcinoma [47] and colorectal cancer [48]. Here, CD209 is linked to hepatocellular carcinoma.